id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2216-0006,FDA,FDA-2016-E-2216,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T05:32:29Z,,0,0,090000648357ae96
FDA-2016-E-2216-0005,FDA,FDA-2016-E-2216,"Determination of Regulatory Review Period for Purposes of Patent
Extension; VELTASSA",Notice,Determinations,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-01-30T04:59:59Z,2017-11-29T16:39:29Z,2017-25761,0,0,0900006482cbbd77
FDA-2016-E-2216-0004,FDA,FDA-2016-E-2216,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,,2017-08-21T16:45:01Z,,0,0,0900006482a8ca55
FDA-2016-E-2216-0003,FDA,FDA-2016-E-2216,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-09-07T04:00:00Z,2016,9,2016-09-07T04:00:00Z,,2016-09-07T16:52:20Z,,0,0,09000064821dd0ae
FDA-2016-E-2216-0002,FDA,FDA-2016-E-2216,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-07-26T04:00:00Z,2016,7,2016-07-26T04:00:00Z,,2016-07-26T13:44:11Z,,0,0,09000064821217d0
FDA-2016-E-2216-0001,FDA,FDA-2016-E-2216,"Patent Extension Application from Senniger Powers LLP (on behalf of Relypsa, Inc)",Other,Application,2016-07-26T04:00:00Z,2016,7,2016-07-26T04:00:00Z,,2016-07-26T13:44:06Z,,0,0,090000648212163c